Hypercytokinemia-induced metabolic encephalopathy in a multiple myeloma patient on hemodialysis undergoing autologous stem cell transplantation: clinical response after plasma exchange.

[1]  M. Gore,et al.  Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Garg,et al.  Do Biochemical Measures Change in Living Kidney Donors? , 2007, Nephron Clinical Practice.

[3]  M. Odeh.  Pathogenesis of hepatic encephalopathy: the tumour necrosis factor‐α theory , 2007, European journal of clinical investigation.

[4]  K. Pittman,et al.  Hyperammonemia encephalopathy: An important cause of neurological deterioration following chemotherapy , 2007, Leukemia & lymphoma.

[5]  P. Li,et al.  Elevation of Pro-Inflammatory Cytokines, C-Reactive Protein and Cardiac Troponin T in Chronic Renal Failure Patients on Dialysis , 2007, Immunological investigations.

[6]  P. Tsang,et al.  Clonal T-large granular lymphocyte proliferation in solid organ transplant recipients. , 2006, Transplantation proceedings.

[7]  Shijie Jin,et al.  Tumor Necrosis Factor-α Induces Neurotoxicity via Glutamate Release from Hemichannels of Activated Microglia in an Autocrine Manner* , 2006, Journal of Biological Chemistry.

[8]  M. Majdan,et al.  Influence of some immune factors on the IL-6 and soluble IL-2 receptors in haemodialysed patients , 2006, International Urology and Nephrology.

[9]  K. Ateş,et al.  Serum C-reactive Protein Level Is Associated with Renal Function and It Affects Echocardiographic Cardiovascular Disease in Pre-Dialysis Patients , 2005, Nephron Clinical Practice.

[10]  M. Nagai,et al.  Efficacy of plasma exchange and methylprednisolone pulse therapy on influenza-associated encephalopathy. , 2005, The Journal of infection.

[11]  M. Odeh,et al.  Relationship between tumor necrosis factor‐alpha and ammonia in patients with hepatic encephalopathy due to chronic liver failure , 2005, Annals of medicine.

[12]  P. Ronco,et al.  Dysregulation of IL-2/IL-2R system alters proliferation of early activated CD4+ T cell subset in patients with end-stage renal failure. , 2005, Clinical nephrology.

[13]  S. Shioda,et al.  Delayed expressed TNFR1 co-localize with ICAM-1 in astrocyte in mice brain after transient focal ischemia , 2004, Neuroscience Letters.

[14]  J. Russell,et al.  TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation , 2004, Journal of Neuroimmunology.

[15]  M. Odeh,et al.  Serum levels of tumor necrosis factor‐α correlate with severity of hepatic encephalopathy due to chronic liver failure , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[16]  U. Loos,et al.  Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma , 2004, Cancer Chemotherapy and Pharmacology.

[17]  S. Morgera,et al.  TNF-alpha elimination with high cut-off haemofilters: a feasible clinical modality for septic patients? , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  H. Nakae,et al.  Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[19]  R. Quigg,et al.  Acute Renal Failure in Endotoxemia Is Caused by TNF Acting Directly on TNF Receptor-1 in Kidney1 , 2002, The Journal of Immunology.

[20]  D. Tarng,et al.  Thiamine deficiency and unexplained encephalopathy in hemodialysis and peritoneal dialysis patients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  A. Munafo,et al.  Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. , 2001, European cytokine network.

[22]  B. Barlogie,et al.  Results of autologous stem cell transplant in multiple myeloma patients with renal failure , 2001, British journal of haematology.

[23]  S. Singhal,et al.  Glomerular filtration rate prior to high-dose melphalan 200 mg/m2as a surrogate marker of outcome in patients with myeloma , 2001, British Journal of Cancer.

[24]  E. Faist,et al.  Removal of Mediators by Continuous Hemofiltration in Septic Patients , 2001, World Journal of Surgery.

[25]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[26]  Junying Yuan,et al.  Apoptosis in the nervous system , 2000, Nature.

[27]  E. Zamagni,et al.  Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure , 2000, Leukemia.

[28]  T. Littlewood,et al.  Encephalopathy complicating high-dose melphalan , 1999, Bone Marrow Transplantation.

[29]  N. Gutiérrez,et al.  Neurological Complications after Autologous Stem Cell Transplantation , 1999, European Neurology.

[30]  K. Shu,et al.  Soluble interleukin 2 receptor in dialyzed patients. , 1998, Artificial organs.

[31]  J. Riera,et al.  Cytokines clearance during venovenous hemofiltration in the trauma patient , 1997 .

[32]  J. Perkins,et al.  High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency , 1997, Bone Marrow Transplantation.

[33]  J. Peters,et al.  Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNFα plasma concentrations , 1997, Intensive Care Medicine.

[34]  J. Lohr,et al.  An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[35]  M. Gerritsen,et al.  Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. , 1997, Journal of immunology.

[36]  J. Sánchez-Izquierdo,et al.  Cytokines clearance during venovenous hemofiltration in the trauma patient. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  J. Wagner,et al.  Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation. , 1996, Bone marrow transplantation.

[38]  W A Buurman,et al.  Tumor necrosis factor: function, release and clearance. , 1996, Critical reviews in immunology.

[39]  C. Demanet,et al.  Serum soluble interleukin 2 receptor in hemodialysis patients treated with recombinant human erythropoietin. , 1995, Blood purification.

[40]  P. Moreau,et al.  Pharmacokinetics of high-dose melphalan in adults: influence of renal function. , 1994, Anticancer research.

[41]  J. Lohr,et al.  Serum‐soluble interleukin‐2 receptors in neuroleptic‐naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia , 1994, Acta psychiatrica Scandinavica.

[42]  F. Berthoux,et al.  Natural serum TNF antagonists in end-stage renal failure and following renal transplantation. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  D. Gouma,et al.  Influence of nephrectomy on tumor necrosis factor clearance in a murine model. , 1993, Journal of immunology.

[44]  R. Falcoff,et al.  Secretion of interleukin-6 (IL-6) by human monocytes stimulated by muramyl dipeptide and tumour necrosis factor alpha. , 1990, Immunology.

[45]  D. Alberts,et al.  Hydrolysis and protein binding of melphalan. , 1978, Journal of pharmaceutical sciences.

[46]  W. M. Heller.  American Hospital Formulary Service , 1959 .

[47]  D. Moravec.  The American Hospital Formulary Service. , 1958, Hospital management.